Key Developments: Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

617.60INR
19 Dec 2014
Price Change (% chg)

Rs-7.50 (-1.20%)
Prev Close
Rs625.10
Open
Rs631.60
Day's High
Rs634.15
Day's Low
Rs616.70
Volume
84,105
Avg. Vol
195,959
52-wk High
Rs671.95
52-wk Low
Rs366.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cipla Ltd's subsidiary to sell equity interest in Jiangsu Cdymax Pharmaceuticals Co. Ltd
Wednesday, 10 Dec 2014 12:23am EST 

Cipla Ltd:Says that Meditab Holdings Limited, Mauritius, a wholly owned subsidiary of the company, has entered into a definitive agreement.Says the agreement is to sell its entire 48.22 pct equity interest in Jiangsu Cdymax Pharmaceuticals Co. Ltd., China to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of 18.5 million.  Full Article

Meda and Cipla sue Apotex to enforce Dymista patents
Wednesday, 3 Dec 2014 02:00am EST 

Meda AB:Says Meda Pharmaceuticals Inc and Cipla Ltd announced that they sued Apotex Inc. and Apotex Corp (Apotex) in Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray.In response to Apotex's submission to the US Food and Drug Administration of an Abbreviated New Drug Application, and accompanying Paragraph IV certification, seeking approval to market a generic version of Meda's Dymista prior to expiration of the Dymista patents.Says the Complaint was filed within 45 days of receiving Apotex's Paragraph IV certification notice, thus triggering an automatic stay preventing the FDA from approving Apotex's ANDA for 30 months from receipt of the notice, unless ordered otherwise by a district court.Meda has the exclusive licenses to U.S. Patent Nos. 8,163,723 and 8,168,620 covering the Dymista composition and its approved uses, which does not expire until 2026.Meda holds the New Drug Application (NDA) to manufacture and market Dymista in the US for the treatment of seasonal allergic rhinitis.Meda and Cipla are jointly represented by attorneys from Sterne, Kessler, Goldstein & Fox P.L.L.C. and Ashby & Geddes, PA.  Full Article

Cipla Ltd announces a distribution agreement with Serum Institute of India
Thursday, 20 Nov 2014 12:40am EST 

Cipla Ltd:Says it has signed a distribution agreement with Serum Institute of India.Says under the agreement, SII will develop and manufacture paediatric vaccined, Cipla will seek European medicines Agency approval and market the products in Europe.Says this collaboration with SII enables cipla to enter into the vaccines segment, continuing commitment to inclusive healthcare for the world.  Full Article

Cipla Ltd asks government to revoke Novartis patents on respiratory drug - Reuters
Wednesday, 29 Oct 2014 08:00pm EDT 

Cipla Ltd:Says it had requested the Indian government to revoke five patents held by Novartis AG on respiratory drug Onbrez, to boost its access in the Indian market - Reuters.Alleged that Novartis has had patents on the drug since 2008/09, but did not make it in India, and instead imported a negligible quantity from Switzerland, leading to a shortage of supply.Says it has potential to manufacture adequate quantities of the drug and make the same available in the country.  Full Article

Cipla Medpro announces collaboration with generic pharmaceutical company
Thursday, 9 Oct 2014 12:02am EDT 

Cipla Ltd:Says Medpro Pharmaceutical (Pty) Ltd- a subsidiary company of Cipla Medpro has entered into a collaboration with TevaPharmaceutical(Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teve).Says the collaboration is restricted to the territory of South Africa.Says the collaboration is a sales and distribution whereby Cipla Medpro will exclusively market Teva's broad pharamaceutical product portfolio in South Africa.  Full Article

Cipla Ltd signs definitive agreement
Saturday, 4 Oct 2014 05:25am EDT 

Cipla Ltd:Signs a definitive agreement with its existing Iranian distributor for setting up a manufacturing facility in Iran.Says the total contribution from the company over the next 3 years will include machinery, equipment, technical know-how and is expected to be about 2.25 billion Indian rupees for a 75 pct stake.Says the proposed investment is subject to completion of certain conditions precedent and applicable regulatory approvals.  Full Article

Gilead Sciences Inc announces generic licensing agreements with Cipla Ltd and others
Monday, 15 Sep 2014 06:30am EDT 

Gilead Sciences Inc:Says it has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries.Agreements allow the companies - Cadila Healthcare, Cipla , Hetero Labs ,Mylan Laboratories, Ranbaxy Laboratories, Sequent Scientific and Strides Arcolab - to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries.Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible.The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities.The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.  Full Article

Cipla Ltd announces commercial collaboration with S&D Pharma
Monday, 8 Sep 2014 06:02am EDT 

Cipla Ltd:Says a commercial collaboration with S&D Pharma in the Czech Republic and Slovakia.This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head.S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.  Full Article

Cipla Ltd's Medispray Laboratories approved acquisition of two manufacturing undertakings
Friday, 5 Sep 2014 08:01am EDT 

Cipla Ltd:Says a subsidiary - Medispray Laboratories Pvt Ltd approved the acquisition of two manufacturing undertakings.The consideration for the above two transactions are 290 mln Indian Rupees and 719.3 mln Indian Rupees respectively.  Full Article

Cipla Ltd and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management
Thursday, 31 Jul 2014 07:30am EDT 

Cipla Ltd:Says Cipla Europe NV and BioQuiddity Inc enters into a commercial collaboration, covering the territory of the European Union and certain other European countries, for BioQuiddity's OneDose ReadyfusOR in regional anesthetic applications for post-surgical pain management.Intends to launch the CE Marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this year.  Full Article

Photo

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

Search Stocks